neoBona检测的性能:一种基于双端大规模并行鸟枪法测序的无细胞DNA非整倍体筛查新方法
这项盲法研究对1000名孕11-13周孕妇的血浆样本(1mL)进行双端大规模并行鸟枪法测序,评估胎儿21、18、13三体筛查性能,988例获得有效结果,47例21三体、10例13三体、29例18三体和901例未受累妊娠均分类正确,新方法可准确预测胎儿三体。
要点
- neoBona检测对21三体的47例全部正确分类,对13三体的10例全部正确分类。
- 30例18三体中29例正确分类,901例未受累妊娠全部正确分类。
- 新多组分t评分无需剔除胎儿分数<4%的样本,可能扩大cfDNA筛查受益人群。
核心结论
- 这种利用双端大规模并行鸟枪法测序进行母体血浆cfDNA分析的新方法能够准确预测胎儿三体。
- 使用新的多组分t评分消除了剔除胎儿分数<4%样本的需要,可能将无创产前cfDNA分析的益处扩展到更大比例的妊娠。
研究设计与样本
- 这是一项盲法研究,纳入1000名在孕11-13周接受胎儿21、18、13三体筛查的孕妇,采集血浆样本1mL。
- 研究包括50例确诊胎儿21三体、30例18三体、10例13三体和910例未受累妊娠。
- neoBona检测采用双端大规模并行鸟枪法测序,同时评估胎儿分数、cfDNA片段大小分布和染色体计数,整合入新分析算法计算各目标染色体的三体似然比(t评分)。
- 每个样本使用染色体特异性 cut-off 分类为三体或未受累,21三体t评分 cut-off 为1.5,18和13三体为3.0。
主要发现
- 988例(98.8%)提供有效结果;12例(1.2%)样本未通过质量控制标准被排除进一步分析,其中9例为整倍体妊娠、3例为21三体妊娠。
- 47例21三体全部正确分类,10例13三体全部正确分类,30例18三体中29例正确分类,901例未受累病例全部正确分类。
- 中位胎儿分数为10.5%(范围0.3-33.8%),胎儿分数<1%的三体和未受累病例均被正确识别。
关键数值与推荐
- 21三体t评分 cut-off 为1.5,18和13三体t评分 cut-off 为3.0。
- 中位胎儿分数为10.5%(范围0.3-33.8%)。
临床怎么用
- 作者认为这种基于双端大规模并行鸟枪法测序的cfDNA分析新方法可准确预测胎儿三体。
- 作者指出使用新的多组分t评分消除了剔除胎儿分数<4%样本的需要,可能将无创产前cfDNA分析的益处扩展到更大比例的妊娠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the performance of screening for fetal trisomies 21, 18 and 13 by cell-free (cf) DNA analysis of maternal blood using a new method based on paired-end massively parallel shotgun sequencing (MPSS). METHODS: This was a blinded study of plasma samples (1mL) obtained from 1000 women undergoing screening for fetal trisomies 21, 18 and 13 at 11-13 weeks' gestation. The study included 50 cases with confirmed fetal trisomy 21, 30 with trisomy 18, 10 with trisomy 13 and 910 unaffected pregnancies. Paired-end MPSS with the neoBona® test allowed simultaneous assessment of fetal fraction, cfDNA fragment size distribution and chromosome counting, which were integrated into a new analysis algorithm to calculate trisomy likelihood ratios (t-score) for each chromosome of interest. Each sample was classified as trisomic or unaffected using chromosome-specific cut-offs set at t-score values of 1.5 for trisomy 21 and 3.0 for trisomies 18 and 13. RESULTS: Valid results were provided for 988 (98.8%) cases; 12 (1.2%) samples, from nine euploid and three trisomy 21 pregnancies, did not pass quality-control criteria and were excluded from further analysis. All 47 cases of trisomy 21, all 10 of trisomy 13, 29 of 30 with trisomy 18 and all 901 unaffected cases were classified correctly. Median fetal fraction was 10.5% (range, 0.3-33.8%) and trisomic and unaffected cases with low fetal fractions of < 1% were identified correctly. CONCLUSIONS: This novel method for cfDNA analysis of maternal plasma, which utilizes paired-end MPSS, can provide accurate prediction of fetal trisomies. Use of a new multicomponent t-score removes the need to reject samples with fetal fraction < 4%, which potentially extends the benefits of non-invasive prenatal cfDNA analysis to a larger proportion of pregnancies. © 2016 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cirigliano V, Ordoñez E, Rueda L, et al. Performance of the neoBona test: a new paired-end massively parallel shotgun sequencing approach for cell-free DNA-based aneuploidy screening. Ultrasound Obstet Gynecol. 2017. PMID: 27981672. doi:10.1002/uog.17386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。